共 52 条
[1]
Fakih MG(2015)Metastatic colorectal cancer: current state and future directions J Clin Oncol 33 1809-1824
[2]
Bai L(2015)Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment Med Oncol 32 469-920
[3]
Zhang DS(2016)Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Onco Targets Ther. 9 1899-9
[4]
Xu RH(2016)Colorectal cancer: overcoming resistance to anti-EGFR therapy—where do we stand? Nat Rev Gastroenterol Hepatol 13 258-70
[5]
Seow HF(2015)Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: toward targeted personalized therapy Drug Resist Updat. 20 39-529
[6]
Yip WK(2016)Antiangiogenic therapy in oncology: current status and future directions Lancet 388 518-307
[7]
Fifis T(2011)Molecular mechanisms and clinical applications of angiogenesis Nature 473 298-2019
[8]
Schirripa M(2015)Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice J Hematol Oncol 8 92-312
[9]
Lenz HJ(2008)Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013-1645
[10]
De Mattia E(2013)Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 303-115